Bausch + Lomb (NYSE:BLCO) received US FDA clearance for its Bi-Blade+ dual-port vitrectomy cutter and Adaptive Fluidics update, expanding its retina surgery toolkit. The company launched the enVista ...

Bausch + Lomb Corporation (NYSE:BLCO) is among the 10 High Growth Canadian Stocks to Buy Now. On April 16, Bausch + Lomb ...

Bausch + Lomb is expanding its ophthalmology portfolio and pipeline, paying Novartis $1.75 billion to acquire a commercialized drug for dry eye disease along with two experimental eye products. The ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced 13 podium and ...

Seven Presentations Will Include Unique Research on the New Biotrue® Hydration Plus Multi-Purpose Solution and Biotrue® Hydration Boost Lubricant Eye Drops Company to Also Host Several Sponsored ...

Eye health products company Bausch + Lomb is teaming up with Walmart to host eye care clinics at dozens of the retailer’s stores nationwide. “Eye Care for My Care” aims to help educate shoppers on the ...

In recognition of Earth Day, two eye care companies shared updates on their efforts to offset and mitigate the environmental ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S.

Eye care company Bausch + Lomb (BLCO) said Friday it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis (NVS), in a move that could help the ...

Bausch + Lomb announced on Monday the debut of its Project Watson line of eye, ear and overall wellness products for dogs. The Project Watson product line is set to include eye and ear washes, eyelid ...

News broke at the end of June that Bausch + Lomb, the eye care specialist spun out of parent company Bausch Health, had opted to pay up to $2.5bn to acquire dry eye disease therapy XIIDRA from ...